Overview

TriMaster: Study of a DPP4 Inhibitor, SGLT2 Inhibitor and Thiazolidinedione as Third Line Therapy in Patients With Type 2 Diabetes.

Status:
Completed

Trial end date:
2021-01-01

Target enrollment:

Participant gender:

Summary

The aim of this project is to identify subgroups of patients with type 2 diabetes that respond well or poorly to particular drugs based on particular clinical characteristics such as their weight or kidney function, to enable better targeting of treatment for a particular individual. This study will test 2 hypotheses of drug response supported by routine clinical and trial data. 600 patients with type 2 diabetes who have suboptimal glycaemic control on dual oral therapy will be recruited to a randomised double-blind crossover study of a DPP4 inhibitor, SGLT2 inhibitor and thiazolidinedione. Each patient will take each study drug in addition to their existing treatment for four months at a time. At the end of each treatment the patient's glucose control will be measured and information about their experience of the drug will be collected.

Phase:

Phase 4

Details

Lead Sponsor:

NIHR Exeter Clinical Research Facility
Royal Devon and Exeter NHS Foundation Trust

Collaborators:

King's College London
Newcastle University
NHS Tayside
Royal Devon and Exeter NHS Foundation Trust
University of Dundee
University of Exeter
University of Glasgow

Treatments:

2,4-thiazolidinedione
Canagliflozin
Dipeptidyl-Peptidase IV Inhibitors
Pioglitazone
Sitagliptin Phosphate